Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial - Concepedia

Concepedia

Publication | Open Access

Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial

DOI Full Paper Access

134

Citations

28

References

2021

Year

Ikuo Hirano, Margaret H. Collins, David A. Katzka, Vincent A. Mukkada, Gary W. Falk, Robin Morey, Nirav K. Desai, Lan Lan, J. E. Williams, Evan S. Dellon

Clinical Gastroenterology and Hepatology

Abstract

In patients with EoE, BOS 2.0 mg twice daily was superior to placebo in improving histologic, symptomatic, and endoscopic outcomes over 12 weeks. BOS 2.0 mg twice daily was well tolerated. ClinicalTrials.gov number: NCT02605837.

References

	Year	Citations

Page 1